October 19, 2015 — Siemens’ PETNET Solutions Inc., a wholly owned subsidiary of Siemens Healthcare, will formulate the VPAC1 molecular biomarker 64Cu TP-3805 exclusively for clinical trials for the biopharmaceutical firm NuView Life Sciences Inc., of Park City, Utah.
Targeting the VPAC1 receptor over-expressed on the surface of malignant cancer cells, 64Cu TP-3805 is being studied for prostate and breast cancer imaging using positron emission tomography/computed tomography (PET/CT) and PET/magnetic resonance imaging (PET/MR).
Thomas Jefferson University and NuView developed a peptide that specifically binds to the VPAC1 receptor found on the surface of mutating cancer cells. The VPAC1 biomarker is a platform technology, for precision in-vivo cancer diagnosis, in-vitro cancer urine screening by identifying shed cancer cells in voided urine and may have application for precision cancer therapy delivery.
As a 64Cu-labeled peptide with a longer half-life (12.7 hours), 64Cu TP-3805 is better suited for clinical trial distribution across a large geographical area than other commonly used PET radiopharmaceuticals.
For more information: www.siemens.com, www.nuviewinfo.com
January 27, 2026 
